These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 34866925)

  • 1. A Web-Based Survey on Factors for Unvaccination and Adverse Reactions of SARS-CoV-2 Vaccines in Chinese Patients with Psoriasis.
    Wang Q; Lv C; Han X; Shen M; Kuang Y
    J Inflamm Res; 2021; 14():6265-6273. PubMed ID: 34866925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A web-based survey of SARS-CoV-2 vaccination and its adverse effects in Chinese postoperative patients with breast cancer: a cross-sectional study.
    Wang X; Shen M; Zhang Q; Wang X; Zhang H; Li T; Hu Y; Xia F; Liao L
    Gland Surg; 2022 Sep; 11(9):1497-1506. PubMed ID: 36221281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: A real life experience.
    Musumeci ML; Caruso G; Trecarichi AC; Micali G
    Dermatol Ther; 2022 Jan; 35(1):e15177. PubMed ID: 34699117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 vaccination in androgen sensitive phenotypes - A study on associated factors for SARS-CoV-2 vaccination and its adverse effects among androgenetic alopecia and benign prostate hyperplasia patients.
    Fan Z; Duan S; Liu F; Shi W; Yang Z; Bai R; Li T; Chen J; Xie H; Li J; Tang Y
    Front Immunol; 2022; 13():919958. PubMed ID: 36119091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis During the COVID-19 Epidemic: A Web-Based Survey.
    Wang Q; Luo Y; Lv C; Zheng X; Zhu W; Chen X; Shen M; Kuang Y
    Patient Prefer Adherence; 2020; 14():1403-1409. PubMed ID: 32884243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [BIOLOGICAL TREATMENT OF PSORIASIS IN TIME OF NEW CORONAVIRUS INFECTION COVID-19].
    Kruglova LS; Pereverzina NO; Rudneva NS; Kamynina NN; Oynotkinova OS
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Aug; 29(Special Issue):1381-1387. PubMed ID: 34792893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    Wang J; Hou Z; Liu J; Gu Y; Wu Y; Chen Z; Ji J; Diao S; Qiu Y; Zou S; Zhang A; Zhang N; Wang F; Li X; Wang Y; Liu X; Lv C; Chen S; Liu D; Ji X; Liu C; Ren T; Sun J; Zhao Z; Wu F; Li F; Wang R; Yan Y; Zhang S; Ge G; Shao J; Yang S; Liu C; Huang Y; Xu D; Li X; Ai J; He Q; Zheng MH; Zhang L; Xie Q; Rockey DC; Fallowfield JA; Zhang W; Qi X
    J Hepatol; 2021 Aug; 75(2):439-441. PubMed ID: 33905793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in Adverse Reactions to an Inactivated SARS-CoV-2 Vaccine Among Medical Staff in China.
    Zhu JS; Zhang MX; Chien CW; Yang WY; Shi GF; Qiu S; Tung TH; Chen HX
    Front Med (Lausanne); 2021; 8():731593. PubMed ID: 34568389
    [No Abstract]   [Full Text] [Related]  

  • 13. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines.
    Bellinato F; Maurelli M; Gisondi P; Girolomoni G
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents.
    Talamonti M; Galluzzo M
    Expert Opin Biol Ther; 2021 Nov; 21(11):1535-1537. PubMed ID: 34357839
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience.
    Skroza N; Bernardini N; Tolino E; Proietti I; Mambrin A; Marchesiello A; Marraffa F; Rossi G; Volpe S; Potenza C
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use].
    Yang ZN; Zhao YY; Li L; Gao HD; Cai Q; Sun XX; Zhang FS; Su JF; Zhang YN; Shu X; Wang XW; Yang YK; Zhang YT; Zhou S; Yang XM
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jun; 42(6):977-982. PubMed ID: 33874701
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.